Table V-ROvarian Cancer. Tumor Response and Quality of Life

StudyTumor Response (%)Quality of Life
9040, Camilleri-Broet et al., 2004GrpNCRPRSDPDTestpComments
no relation between tHER2 expression level and response;
ScaleDomainF/UGrpnmn±sd
10820, Bookman et al., 2003GrpNCRPRSDPDTestpComments
IHC3+ more likely to experience cycle 1 toxicity
ScaleDomainF/UGrpnmn±sd
0.023
11720, Bowman et al., 2002GrpNCR+PRSDPD?TestpComments
high HER2 (not defined) associated with CA125 progression
ScaleDomainF/UGrpnmn±sd
0.026
13450, Campos et al., 2001GrpNCRPRSDPDTestpComments
≥50%↓ in CA125
ScaleDomainF/UGrpnmn±sd
IHC+45050FE0.579
IHC-303011572
IHC?241729504
15150, Hengstler et al., 1999GrpNCR+PRSD+PDTestpCommentsScaleDomainF/UGrpnmn±sd
17300, Di Leo et al., 1995GrpNCRPRSDPDTestpCommentsScaleDomainF/UGrpnmn±sd
IHC+82575FE0.602
IHC-141486

From: Appendix C. Evidence Data Abstraction Tables

Cover of HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors
HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors.
Evidence Reports/Technology Assessments, No. 172.
Seidenfeld J, Samson DJ, Rothenberg BM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.